Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | PER2 | O15055 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832925 | 1.00 | HDAC1 (0.38) | HDAC1HDAC8HDAC6MKNK1FPR1 | |
| SCHEMBL21314738 | 1.00 | HDAC1 (0.38) | HDAC1HDAC8HDAC6MKNK1FPR1 | |
| SCHEMBL25868506 | 0.86 | PER2 (0.37) | HDAC1HDAC8HDAC6HDAC5P2RX7 | |
| SCHEMBL31165435 | 0.80 | CCR1 (0.44) | HDAC1HDAC8HDAC6MKNK1P2RX7 | |
| SCHEMBL30832909 | 0.78 | RAPGEF3 (0.39) | HDAC1HDAC8HDAC6HDAC5NOTUM | |
| SCHEMBL21314781 | 0.78 | RAPGEF3 (0.39) | HDAC1HDAC8HDAC6HDAC5NOTUM | |
| SCHEMBL31440066 | 0.78 | NOTUM (0.48) | HDAC1HDAC8HDAC6P2RX7NOTUM | |
| SCHEMBL21314774 | 0.76 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL21314771 | 0.76 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL30832924 | 0.76 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868052-B | Phenyl pyrrolidone formyl peptide 2 receptor agonist | 百时美施贵宝公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3981767-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3762380-B1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371378-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-02 | — | — | US | disclosed |
| US-11117861-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-14 | — | — | US | disclosed |
| CN-111868052-A | Phenylpyrrolidinone formyl peptide 2 receptor agonists | 百时美施贵宝公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200255375-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676431-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190270704-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
| US-10676431-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
| US-20190270704-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
| US-11117861-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
| US-20200255375-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
| US-20210371378-A1 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | HDAC1 3925/4885HDAC8 3818/4885HDAC6 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.